Provectus Biopharmaceuticals to Participate in Panel at Third International Conference on the Progress of Regenerative Medici...
April 27 2016 - 6:00AM
Business Wire
Panel: Combination Therapies at 10:05 AM,
April 29, with Grant McArthur
Conference Runs April 28–30, 2016, in
Vatican City
Provectus Biopharmaceuticals, Inc. (NYSE MKT:PVCT,
www.pvct.com), a clinical-stage oncology and dermatology
biopharmaceutical company ("Provectus" or “The Company”), today
announced that it will be participating in a panel discussion at
Cellular Horizons: The Third International Conference on the
Progress of Regenerative Medicine and its Cultural Impact. The
conference will be held April 28-30, 2016, in Vatican City, and
hosted by the Vatican’s Pontifical Council for Culture, The Stem
For Life Foundation and the STOQ (Science, Theology and the
Ontological Quest) Foundation.
Peter Culpepper, interim CEO and COO of Provectus, said, “We are
deeply honored to be participating in this global conference and to
be doing so with one of our investigators, Grant McArthur, who
leads investigations into new cancer treatments that control cell
growth, division and differentiation.
“Provectus and its investigators are engaged in multiple studies
that are of relevance to the conference. Our phase 3 study of
intralesional PV-10 as a stand alone treatment of locally advanced
cutaneous melanoma addresses early-stage advanced melanoma, while
our study of IL PV-10 in combination with a systemic immune
checkpoint inhibition for treatment of metastatic melanoma,
specifically Merck’s Keytruda (pembrolizumab), addresses more
advanced-stage melanoma.”
Mr. Culpepper concluded, “Finally, our research into the
mechanism of action for PV-10 suggests that there are treatments
that harness the body’s own disease fighting powers that could
bring new tools to the medical profession in treating many kinds of
disease.”
“The Third International Conference on the Progress of
Regenerative Medicine and Its Cultural Impact will rally the world
around a powerful idea ─ that the cells of our bodies hold the
potential to vanquish disease, reduce global suffering and inspire
hope for people around the world living with illness. We will
discuss immunotherapies for autoimmune diseases and cancer and
explore how combination therapies will allow maximizing the immune
system for more effective therapy,” said Dr. Robin Smith, President
of The Stem For Life Foundation.
About The Stem For Life Foundation
The Stem For Life Foundation (SFLF) is the educational and
advocacy subsidiary of The Cura Foundation and is devoted to
fostering global awareness of the potential for regenerative
medicine to treat and cure a range of deadly diseases and
debilitating medical conditions, as opposed to merely treating
their symptoms. The Foundation stands at the forefront of a
fundamental shift away from traditional drug treatment in favor of
amplifying the body’s natural repair mechanisms to vanquish
disease. For more information on The Stem For Life Foundation,
please visit http://www.stemforlife.org. To follow the Vatican
event on Twitter, please join the conversation @StemForLife or via
the hashtag #UNITETOCURE.
About Provectus Biopharmaceuticals, Inc.
Provectus Biopharmaceuticals, Inc., specializes in developing
oncology and dermatology therapies. PV-10, its novel
investigational drug for cancer, is designed for injection into
solid tumors (intralesional administration), thereby reducing
potential for systemic side effects. Its oncology focus is on
melanoma, breast cancer and cancers of the liver. The Company has
received orphan drug designations from the FDA for its melanoma and
hepatocellular carcinoma indications. PH-10, its topical
investigational drug for dermatology, is undergoing clinical
testing for psoriasis and atopic dermatitis. Provectus has
completed Phase 2 trials of PV-10 as a therapy for metastatic
melanoma, and of PH-10 as a topical treatment for atopic dermatitis
and psoriasis. Information about these and the Company's other
clinical trials can be found at the NIH
registry, www.clinicaltrials.gov. For additional information
about Provectus, please visit the Company's website
at www.pvct.com or contact Porter, LeVay & Rose,
Inc.
FORWARD-LOOKING STATEMENTS: This release contains
"forward-looking statements" as defined under U.S. federal
securities laws. These statements reflect management's current
knowledge, assumptions, beliefs, estimates, and expectations and
express management's current views of future performance, results,
and trends and may be identified by their use of terms such as
"anticipate," "believe," "could," "estimate," "expect," "intend,"
"may," "plan," "predict," "project," "will," and other similar
terms. Forward-looking statements are subject to a number of risks
and uncertainties that could cause our actual results to materially
differ from those described in the forward-looking statements.
Readers should not place undue reliance on forward-looking
statements. Such statements are made as of the date hereof, and we
undertake no obligation to update such statements after this
date.
Risks and uncertainties that could cause our actual results to
materially differ from those described in forward-looking
statements include those discussed in our filings with the
Securities and Exchange Commission (including those described in
Item 1A of our Annual Report on Form 10-K for the year ended
December 31, 2015) and the following:
- our determination, based on guidance
from the FDA, whether to proceed with or without a partner with the
fully enrolled phase 3 trial of PV-10 to treat locally advanced
cutaneous melanoma and the costs associated with such a trial if it
is necessary to complete (versus interim data alone);
- our determination whether to license
PV-10, our investigational drug product for melanoma and other
solid tumors such as cancers of the liver, if such licensure is
appropriate considering the timing and structure of such a license,
or to commercialize PV-10 on our own to treat melanoma and other
solid tumors such as cancers of the liver;
- our ability to license PH-10, our
investigational drug product for dermatology, on the basis of our
phase 2 atopic dermatitis and psoriasis results, which are in the
process of being further developed in conjunction with mechanism of
action studies; and
- our ability to raise additional capital
if we determine to commercialize PV-10 and/or PH-10 on our own,
although our expectation is to be acquired by a prospective
pharmaceutical or biotech concern prior to commercialization.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160427005243/en/
Provectus Biopharmaceuticals, Inc.Peter R. Culpepper,
866-594-5999 #30Interim CEO, COOorInvestor RelationsPorter, LeVay
& Rose, Inc.Marlon Nurse, 212-564-4700DM, SVPorAllison +
PartnersTodd Aydelotte, 646-428-0644Managing Director - Media
RelationsorStem For LifeAllison + PartnersLinda Burns,
+1-646-428-0606Linda@allisonpr.com
Provectus Biopharmaceuti... (QB) (USOTC:PVCT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Provectus Biopharmaceuti... (QB) (USOTC:PVCT)
Historical Stock Chart
From Apr 2023 to Apr 2024